US prevalence
38M US adults / 11.6% population
Source: CDC 2024
ConditionICD-10: E11.9
Type 2 Diabetes
Type 2 diabetes is a chronic metabolic disorder where the body becomes resistant to insulin, leading to elevated blood sugar (hyperglycemia). It affects ~37 million Americans (~11% of adults) and is the leading cause of kidney failure, lower-limb amputations, and adult-onset blindness. Early detection and consistent management dramatically reduce complications.
Quick answer
UpdatedType 2 diabetes is a chronic metabolic disease characterized by insulin resistance + relative insulin deficiency, leading to elevated blood glucose. Approximately 38 million US adults have T2D (11.6% of population), with another 98 million having prediabetes. GLP-1 receptor agonists (Ozempic, Mounjaro, Rybelsus, Trulicity) are first- or second-line therapies that improve glycemic control while typically reducing weight and (for some) reducing cardiovascular event risk.
- US prevalence: 38 million adults (~11.6%)
- CDC National Diabetes Statistics Report 2024
- Annual US cost: $413 billion (direct + indirect)
- ADA Economic Costs of Diabetes 2022
- GLP-1 efficacy: A1C reduction 1.5-2.3 percentage points
- SUSTAIN-6 + SURPASS-2 trial data
- CV risk reduction: 12-26% MACE reduction (semaglutide/dulaglutide/liraglutide)
- SUSTAIN-6, REWIND, LEADER trials
- Common comorbidities: Obesity, hypertension, CKD, retinopathy
- 85%+ of T2D patients have BMI ≥25
Annual US burden
$413 billion
Annual US direct + indirect cost
Source: ADA 2022
GLP-1 role
First- or second-line therapy per ADA Standards of Care; preferred over older sulfonylureas due to lower hypoglycemia risk + cardiovascular benefits.
Key takeaways
- • GLP-1 RAs and GLP-1/GIP agonists are first-line injectables after metformin in 2025 ADA guidelines.
- • HbA1c reductions of 1.0-2.0 points are typical at maintenance dose.
- • Semaglutide and tirzepatide have proven cardiovascular benefits in T2D.
- • Not insulin — risk of hypoglycemia is low unless combined with insulin or sulfonylureas.
- • Coverage for T2D indication is generally broader than for weight-only indications.
Key facts
- •37.3 million Americans have type 2 diabetes (CDC)
- •GLP-1 medications lower A1c by 1–2% and aid weight loss
- •Ozempic, Mounjaro, Trulicity, Rybelsus are FDA-approved for T2D
- •Most commercial insurance plans cover GLP-1 for diabetes (vs weight loss)
- •Newer GLP-1s offer cardiovascular benefits beyond glucose control
Why GLP-1 medications
GLP-1 agonists enhance glucose-dependent insulin secretion and suppress glucagon, lowering blood sugar without high hypoglycemia risk. Recent CVOT trials (LEADER, SUSTAIN-6, REWIND, SURPASS-CVOT) show cardiovascular benefits in T2D patients with established heart disease.
GLP-1 drugs prescribed for Type 2 Diabetes
Each row links to its full review with current pricing, FDA status, and the best telehealth providers offering it. Discuss with your prescriber — these are treatment options, not personal recommendations.
- Ozempic$968–$1100/mo
semaglutide
98/100 matchFDA-approved for type 2 diabetes + cardiovascular risk reduction
Compare providers - Mounjaro$1023–$1330/mo
tirzepatide
96/100 matchFDA-approved for type 2 diabetes — strongest A1c reduction in head-to-head trials
Compare providers - Trulicity$987/mo
dulaglutide
92/100 matchFDA-approved for type 2 diabetes + cardiovascular risk reduction
Compare providers - Rybelsus$850–$1100/mo
semaglutide
90/100 matchFDA-approved for type 2 diabetes — oral semaglutide
Compare providers
| Drug | Avg monthly cost | Indication match | Notes | Best providers |
|---|---|---|---|---|
| Ozempic semaglutide | $968–$1100/mo | 98/100 | FDA-approved for type 2 diabetes + cardiovascular risk reduction | Compare |
| Mounjaro tirzepatide | $1023–$1330/mo | 96/100 | FDA-approved for type 2 diabetes — strongest A1c reduction in head-to-head trials | Compare |
| Trulicity dulaglutide | $987/mo | 92/100 | FDA-approved for type 2 diabetes + cardiovascular risk reduction | Compare |
| Rybelsus semaglutide | $850–$1100/mo | 90/100 | FDA-approved for type 2 diabetes — oral semaglutide | Compare |
Educational only. Discuss with your prescriber — these are treatment options, not personal recommendations. Indication-match scores reflect FDA approval status and published clinical evidence, not individual patient suitability.
Common symptoms
- Frequent urination, especially at night
- Increased thirst and dry mouth
- Unexplained weight loss or weight gain
- Fatigue and irritability
- Blurred vision
- Slow-healing cuts, frequent infections
- Numbness or tingling in hands and feet (later stage)
How type 2 diabetes is diagnosed
Diagnosis requires one of: A1c ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL, 2-hour oral glucose tolerance test ≥ 200 mg/dL, or random glucose ≥ 200 mg/dL with classic symptoms. Diagnosis should be confirmed with repeat testing unless symptoms are obvious. A1c reflects 3-month average glucose; ideal target is generally < 7% for most adults.
Treatment options
Metformin (first-line)
Cheap, well-tolerated, reduces glucose production by liver. A1c reduction: 1–2%. Used in 80% of T2D patients.
GLP-1 agonists
Ozempic, Trulicity, Mounjaro, Rybelsus. A1c reduction: 1–2% + weight loss + CVD risk reduction. Now ADA-recommended for T2D with established CVD or high CVD risk.
SGLT2 inhibitors
Jardiance, Farxiga, Invokana. Cause kidney to excrete excess glucose in urine. Cardiovascular and renal benefits.
Insulin
Used when other meds insufficient, or in newly-diagnosed patients with very high A1c (>10%). Long-acting (basal) + rapid-acting (mealtime).
Compare telehealth providers for Type 2 Diabetes
SponsoredRanked by our editorial score. Visit a partner to check current pricing and eligibility — we never sell medications.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
- Ro· from $145/moHighest score in our rubricTelehealth · Type 2 Diabetes care
- Hers· from $99/moFDA-approved brand medicationTelehealth · Type 2 Diabetes care
- Hims· from $99/moNo video visit requiredTelehealth · Type 2 Diabetes care
- LifeMD· from $89/moBills your insuranceTelehealth · Type 2 Diabetes care
Lifestyle & self-care
- Mediterranean diet — emphasizes vegetables, whole grains, fish, olive oil
- Limit added sugars and refined carbs
- Exercise 150+ min/week aerobic + 2x/week resistance training
- Lose 5–10% of body weight if overweight (can put T2D in remission for some)
- Don't smoke — tobacco accelerates diabetic complications
- Annual eye, kidney, and foot exams
When to see a doctor
Make an appointment if you have:
- →Frequent urination, thirst, fatigue (especially with family history)
- →BMI ≥ 25 with sedentary lifestyle
- →Family history of T2D, gestational diabetes
- →High blood pressure or abnormal cholesterol
- →Age ≥ 45 (annual screening recommended)
Medications for Type 2 Diabetes
Trulicity
dulaglutide
GLP1Zoom score: 5.0/10
Rybelsus
semaglutide
GLP1Zoom score: 5.8/10
From $850/mo
Ozempic
semaglutide
GLP1Zoom score: 5.8/10
From $968/mo
Mounjaro
tirzepatide
GLP1Zoom score: 6.6/10
From $1023/mo
Not sure which medication is right for you?
Take our 60-second quiz and get a personalized match.
Take the quizType 2 Diabetes& GLP-1 — frequently asked questions
Can GLP-1 medications treat Type 2 Diabetes?
GLP-1 agonists enhance glucose-dependent insulin secretion and suppress glucagon, lowering blood sugar without high hypoglycemia risk. Recent CVOT trials (LEADER, SUSTAIN-6, REWIND, SURPASS-CVOT) show cardiovascular benefits in T2D patients with established heart disease.
Which GLP-1 medications are used for Type 2 Diabetes?
GLP-1 options associated with Type 2 Diabetes include Ozempic, Mounjaro, Rybelsus, Trulicity, Soliqua. FDA approval is indication-specific — confirm the right medication with your prescriber.
Is GLP-1 therapy FDA-approved for Type 2 Diabetes?
FDA approval is indication-specific. Some GLP-1 medications are FDA-approved for Type 2 Diabetes or a closely related indication, while others are prescribed off-label under clinical judgment. Always verify the approved indication for your specific medication.
Sources
- ADA Standards of Care 2025
- CDC National Diabetes Statistics Report
- SUSTAIN-6 — semaglutide CV outcomes
- SURPASS-CVOT — tirzepatide vs dulaglutide CV outcomes
Educational content; not a substitute for professional medical advice. Always consult a licensed clinician.
Diagnostic algorithm
How Type 2 diabetes is diagnosed
Who diagnoses: Primary care provider, endocrinologist. This is the standard clinical algorithm — not self-diagnosis guidance. Always work with your clinician for actual diagnosis.
- 1
Screening test
Fasting plasma glucose OR HbA1c blood draw
Threshold: A1C 5.7-6.4% = prediabetes; ≥6.5% = diabetes
- 2
Confirmatory test
Repeat A1C or fasting glucose on separate day to confirm
Threshold: Two abnormal results required for diagnosis
- 3
Optional oral glucose tolerance test (OGTT)
When A1C and FPG are conflicting or borderline
Threshold: 2-hour OGTT ≥200 mg/dL = diabetes
- 4
Workup if confirmed
Lipid panel, kidney function (eGFR + ACR), liver enzymes, retinal exam baseline
Threshold: Establishes comorbidity baseline
- 5
Treatment initiation
Lifestyle counseling + metformin (typically first-line) ± GLP-1 if obese or CVD risk
Source: ADA Standards of Care in Diabetes (annual update)
Treatment decision criteria
When does a GLP-1 fit Type 2 Diabetes?
Criteria prescribers commonly weigh. Treatment decisions are your prescriber's — these are the factors that inform that decision.
Consider GLP-1 if…
- A1C above goal after metformin monotherapy
- Concurrent obesity (BMI ≥27) — added weight benefit
- Established cardiovascular disease — choose semaglutide/dulaglutide/liraglutide for CV outcomes data
- Need to avoid hypoglycemia (e.g., elderly, sulfonylurea intolerance)
- Renal protection desired — semaglutide showed CKD benefit (FLOW trial)
Try alternatives first if…
- Newly diagnosed without comorbidities — metformin first
- A1C target achievable with lifestyle alone (mild T2D)
- History of medullary thyroid cancer or MEN 2 (contraindication)
- History of pancreatitis or gastroparesis
- Pregnancy planning or current pregnancy
First-line alternatives for Type 2 Diabetes
- Metformin
- ADA-recommended first-line; low cost, no hypoglycemia, modest weight benefit
- SGLT2 inhibitors
- CV + renal benefit; alternative when GLP-1 contraindicated
- DPP-4 inhibitors
- Oral, well-tolerated, weight-neutral; less potent than GLP-1
- Insulin
- When other agents insufficient; required for late-stage T2D
Authoritative sources on Type 2 Diabetes
- Type 2 diabetes — NIH — NIDDK
- Diabetes basics — CDC